I know that many of you believe analysts' reports are out of touch with reality, but since reality seems out of touch with itself these days, I'd post what Wedbush has to say:
1. target of 38 2. Synergy results on target for Q4 13 3. Saturn results on target for Q4 13 4. FDA states Synergy trial alone would be acceptable for submission 5. OGXI continues to evaluate the proper background regimen that 427 can be used in combination with before beginning 011 in NSCLC 6. outperform maintained
I thought 011 in prostate was on target for Q4 12 or Q1 13. Maybe that is realistic and OGXI playing it safe with those targets stated in Wedbush. Doesn't really matter much to me. 011 in prostate hits a home run on pain or survival will IMO trigger buyout by TEVA. NSCLC and 427 is gravy after that.
What an interesting day. It is easy to say we can weather a storm until you stare it in the face. I was lucky today to be hard at work with no time for distractions. Or am I naive? I shouldn't be working and should watch this stock?
Who knows. Reality isn't much of an anchor anymore.